Physician profile
Christopher Leonard Vulin
NPI 1801870126
$8,479.01
in general payments reported to CMS, 2019-2025
42 companies · $2,252 in 2025
The $2,252 reported for 2025 was more than what 82% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $694 · 2020: $213 · 2021: $1,038 · 2022: $1,019 · 2023: $1,780 · 2024: $1,482 · 2025: $2,252.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,456 · Gift: $49.95 · Education: $8.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,456.21 |
| Gift | $49.95 |
| Education | $8.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $1,015.78 | 2019-2025 | Xtandi |
| Pfizer INC. | $643.77 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $603.70 | 2023-2025 | Gemtesa, Orgovyx |
| Dendreon Pharmaceuticals LLC | $599.56 | 2021-2025 | Provenge |
| Accord Healthcare, INC. | $510.30 | 2022-2025 | |
| Ferring Pharmaceuticals INC. | $492.18 | 2024-2025 | Adstiladrin |
| Myriad Genetic Laboratories, INC. | $440.75 | 2023 | Prolaris |
| Bayer Healthcare Pharmaceuticals INC. | $403.53 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $371.21 | 2021-2025 | Keytruda, Welireg, Lynparza |
| Urogen Pharma, INC. | $353.87 | 2022-2025 | |
| Boston Scientific Corporation | $353.62 | 2019-2022 | |
| Janssen Biotech, INC. | $332.70 | 2020-2025 | Erleada, Akeega, Balversa |
| Astrazeneca Pharmaceuticals LP | $308.65 | 2021-2025 | Lynparza |
| Abbvie INC. | $273.94 | 2022-2025 | Lupron Depot, Botox |
| Procept Biorobotics Corporation | $182.09 | 2025 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Vulin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.